Cue Biopharma (CUE) Short-term Investments (2017 - 2025)

Cue Biopharma has reported Short-term Investments for 8 years, with the latest figure at $1.1 million in Q4 2025.

• Quarterly Short-term Investments rose 17.65% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 17.65% YoY) and the FY2025 annual result came in at $1.1 million, up 17.65% from the prior year.
• Short-term Investments fell to $1.1 million in Q4 2025 per CUE's latest filing, from $1.7 million in the prior quarter.
• Over five years, Short-term Investments peaked at $29.5 million in Q3 2022 and troughed at $287000.0 in Q4 2023.
• A 4-year average of $7.4 million and a median of $1.4 million in 2025 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments tumbled 98.84% in 2023, then jumped 223.69% in 2024.
• Over 4 years, Short-term Investments stood at $24.7 million in 2022, then sank by 98.84% to $287000.0 in 2023, then surged by 223.69% to $929000.0 in 2024, then advanced by 17.65% to $1.1 million in 2025.
• According to Business Quant data, Short-term Investments over the past three periods registered $1.1 million, $1.7 million, and $470000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.